

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 63730

Title: COVID-19 Infection or infection-related medical Treatment associated with immunosuppression may trigger HBV Reactivation

Reviewer's code: 05086666

Position: Peer Reviewer

Academic degree: BSc, DPhil, MBBS, MRCP

Professional title: Doctor

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-03 16:14

Reviewer performed review: 2021-02-03 16:28

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The authors describe a case of HBV reactivation in a patient with chronic HBV who was hospitalised for COVID19. This is a short and focused report of an important new observation and could inform clinical care of patients with HBV and Covid19. I would suggest that the authors provide more details about the patient with HBV including: 1. serology results for surface antigen and antibody and e antigen and antibody 2. any details for the severity of liver disease - did the patient have a liver biopsy in the past, ? what was the fibrosis stage? did the patient have any non-invasive assessment with liver stiffness measurement, ELF test, FIB4 or other non-invasive test.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 63730

Title: COVID-19 Infection or infection-related medical Treatment associated with immunosuppression may trigger HBV Reactivation

Reviewer's code: 05038862

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-09 20:37

Reviewer performed review: 2021-02-09 21:32

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

-There is no recommendation to combine adefovir plus entecavir for HBV treatment unless there is entecavir resistance, you “ may” add adefovir [although shifting to tenofovir is the recommended approach], however, you excluded drug resistance in the case history? how can you justify?? -we need baseline PCR to accurately define reactivation? -what was the status of HBsAg at baseline? -We think elevation before methylprednisolone is due to lopinavir/ritonavir not covid-19 treatment? -what was the dose of Methylprednisolone? -Are 6 days being sufficient for steroids to cause reactivation of HBV? usually occurs at 4-6 weeks -As long as HBV resistance genes was tested and negative for entecavir and adefovir dipivoxil, why retreatment with tenofovir was initiated? -based on the lack of evidence of the role of steroids in the possible reactivation, we think the title and the conclusion should only raise the question about the possible role of COVID-19 in reactivation, not the COVID treatment

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 63730

Title: COVID-19 Infection or infection-related medical Treatment associated with immunosuppression may trigger HBV Reactivation

Reviewer's code: 05633255

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-06 22:44

Reviewer performed review: 2021-02-18 21:11

Review time: 11 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

- references should ordered in the text (e.g. ref [4] appear before ref [2] and [3]). -
Abstract: Should add more details about the case - Discussion: need to add more
discussion about the case - Figures 1 and 2: what is the meaning of Y-axis? Also, not
mention in the text.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 63730

Title: COVID-19 Infection or infection-related medical Treatment associated with immunosuppression may trigger HBV Reactivation

Reviewer's code: 05038862

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-03-05 23:16

Reviewer performed review: 2021-03-08 05:51

Review time: 2 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

No further comments